Halofenate is an inhibitor for hypertriglyceridemia, effectively lowering serum triglyceride levels while having minimal impact on serum cholesterol. Additionally, it reduces serum uric acid and promotes uric acid excretion independent of glomerular filtration rate. Halofenate is associated with a significant increase in plasma thyroxine (T4), along with reductions in protein-bound iodine and T4. It can displace T4 from thyroid-binding proteins, which may influence thyroid function in the body.